Is Madrigal Pharmaceuticals Stock a Buy? [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
It wasn't just an important breakthrough for the mid-cap biotech; Rezdiffra became the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-alcoholic steatohepatitis (NASH). These positive developments have helped jolt Madrigal's stock. The shares are up by almost 24% since the year started, while the S&P 500 has gained 14% as of this writing. Is Madrigal still a buy at current levels? Let's find out. There is competition on the way NASH is caused by a buildup of fat in the liver leading to scarring, also known as fibrosis or cirrhosis when it is particularly severe. Earning the first approval in this field is quite an accomplishment for Madrigal. That's especially the case since the FDA did not require that patients get a liver biopsy before being prescribed Rezdiffra, which makes the medicine more accessible. However, there are a few things to keep an eye on. First, Rezdiffra followed the accelerated approval pathway, meaning it w
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Is Madrigal Pharmaceuticals a Millionaire Maker? [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Cantor Fitzgerald. They set a "neutral" rating on the stock.MarketBeat
- Where Will Madrigal Pharmaceuticals Be in 3 Years? [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $382.00 price target on the stock.MarketBeat
- Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress [Yahoo! Finance]Yahoo! Finance